| |
The CRO Awards recognize Contract Research Organizations (CROs) for their exceptional contributions to clinical research and development. These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. LEARN MORE AND ENTER
|
|
| By Gabrielle Masson Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery. |
|
|
|
By Kevin Dunleavy At the European Society of Cardiology conference in London, Alnylam presented positive data from the phase 3 HELIOS-B trial which assessed RNA silencer Amvuttra (vutrisiran) as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). |
By James Waldron Sanofi is still set on taking its multiple sclerosis med tolebrutinib drug to the FDA, executives have told Fierce Biotech, despite the BTK inhibitor falling short in two of three phase 3 trials that read out on Monday. |
By Fraiser Kansteiner Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday. Semaglutide also led to a 41% lower risk of worsening HF, according to a pooled analysis of four Novo Nordisk trials. |
|
Shape the Future of Life Sciences Submissions for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Click to submit your entry for our new 2024 category: AI Innovation. Enter now!
|
|
By Fraiser Kansteiner In tandem with a data drop on its Duchenne muscular dystrophy candidate in patients suited to exon 51 skipping therapy, Dyne Therapeutics has announced a slew of executive changes, including multiple appointments and departures. |
By Fraiser Kansteiner Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant. |
By Conor Hale The trial’s long-awaited results were once expected to settle some of the differences between two previous examinations of the company’s MitraClip approach. |
By Angus Liu Novartis is further bolstering its radiotherapy infrastructure with a brand-new facility and the expansion of an existing site that will bring critical production of radioactive isotopes in house in the U.S. |
By Darren Incorvaia Many microbes are extremophiles, capable of surviving conditions that would spell instant death for you and me. From deep-sea hydrothermal vents to boiling hot springs, these single-celled creatures have evolved special tools to help them thrive in tough places. Researchers have long wanted to harness these tools for human applications. |
By Andrea Park A new appointee with more than two decades of comms experience will soon take the reins of Takeda’s worldwide brand strategy. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "Podnosis," two experts break down the history of plastics use in the healthcare sector and what it would take for an organization to phase them out. |
|
|---|
|
|
|
Thursday, September 5, 2024 | 10am ET / 7am PT It can be difficult to gauge a brand’s success, at pre and post-launch stages, without access to market, product, and indication-specific benchmarks that evaluate performance in several key areas. Learn how Market Research provides actionable connected intelligence to improve decision-making. Register now.
|
|
| WhitepaperStay ahead in biopharma product logistics with the latest insights on cold, ultra-cold and cryogenic storage solutions. Sponsored by: Cardinal HealthTM 3PL Services |
| WhitepaperDSCSA Compliance with a Trusted Partner Sponsored by: BioCare |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| eBookStart leveraging AI to enhance the patient experience while improving personalization, navigation and adherence with the latest free eBook by RxPx. Sponsored by: RxPx |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
